1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.1. Qualitative Research
2.1.1. Primary & Secondary Sources

2.2. Quantitative Research
2.2.1. Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.4. Assumption for the Study

2.5. Market Size Estimation

2.6. Data Triangulation

Executive Summary: Global & Japan Hemophilia Treatment Market

4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.2. Manufacturer
4.1.3. Distributor
4.1.4. End User

4.2. Industry Outlook
4.2.1. Hemophilia Prevalence Overview
4.2.2. Recent Advancement in Gene Therapy for Hemophilia

4.3. PESTLE Analysis

4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition

4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Challenges
4.5.3. Opportunity
4.5.4. Key Trends

4.6. Market Growth and Outlook
4.6.1. Market Revenue Estimates and Forecast (US$ Bn), 2020-2033
4.6.2. Price Trend Analysis

4.7. Competition Dashboard
4.7.1. Market Concentration Rate
4.7.2. Company Market Share Analysis (Value %), 2024
4.7.3. Competitor Mapping & Benchmarking
4.7.4. Pipeline Analysis

5.1. Key Insights

5.2. Market Size and Forecast, 2020-2033 (US$ Bn)
5.2.1. Hemophilia A
5.2.2. Hemophilia B
5.2.3. Hemophilia C
5.2.4. Others

6.1. Key Insights

6.2. Market Size and Forecast, 2020-2033 (US$ Bn)
6.2.1. Recombinant coagulation factor concentrates 
6.2.2. Plasma-derived coagulation factor concentrates
6.2.3. Desmopressin
6.2.4. Antifibrinolytic agents
6.2.5. Gene therapy products
6.2.6. Others

7.1. Key Insights

7.2. Market Size and Forecast, 2020-2033 (US$ Bn)
7.2.1. Pediatric
7.2.1.1. 0 to 4 yrs
7.2.1.2. 5 to 13 yrs
7.2.1.3. 14 to18 yrs
7.2.2. Adult
7.2.2.1. 19 to 44 yrs
7.2.2.2. 45+ yrs

8.1. Key Insights

8.2. Market Size and Forecast, 2020-2033 (US$ Bn)
8.2.1. On-Demand Treatment
8.2.2. Prophylactic Treatment
8.2.3. Immune Tolerance Induction (ITI) Therapy

9.1. Key Insights

9.2. Market Size and Forecast, 2020-2033 (US$ Bn)
9.2.1. Intravenous 
9.2.2. Subcutaneous

10.1. Key Insights

10.2. Market Size and Forecast, 2020-2033 (US$ Bn)
10.2.1. Hospitals
10.2.2. Specialty Clinics
10.2.3. Home Care Settings
10.2.4. Hemophilia Treatment Centers (HTCs)

11.1. Key Insights

11.2. Market Size and Forecast, 2020-2033 (US$ Bn)
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Online Pharmacies

12.1. Key Insights

12.2. Market Size and Forecast, 2020 - 2032 (US$ Bn) 
12.2.1. North America
12.2.1.1. The U.S.
12.2.1.2. Canada
12.2.1.3. Mexico
12.2.2. Europe
12.2.2.1. Western Europe
12.2.2.1.1. The UK
12.2.2.1.2. Germany
12.2.2.1.3. France
12.2.2.1.4. Italy
12.2.2.1.5. Spain
12.2.2.1.6. Rest of Western Europe
12.2.2.2. Eastern Europe
12.2.2.2.1. Poland 
12.2.2.2.2. Russia
12.2.2.2.3. Rest of Eastern Europe
12.2.3. Asia Pacific
12.2.3.1. China
12.2.3.2. India
12.2.3.3. Japan
12.2.3.4. South Korea
12.2.3.5. Australia & New Zealand
12.2.3.6. ASEAN
12.2.3.6.1. Cambodia
12.2.3.6.2. Indonesia
12.2.3.6.3. Malaysia
12.2.3.6.4. Philippines
12.2.3.6.5. Singapore
12.2.3.6.6. Thailand
12.2.3.6.7. Vietnam
12.2.3.7. Rest of Asia Pacific
12.2.4. Middle East & Africa
12.2.4.1. UAE
12.2.4.2. Saudi Arabia
12.2.4.3. South Africa
12.2.4.4. Rest of MEA 
12.2.5. South America
12.2.5.1. Argentina
12.2.5.2. Brazil
12.2.5.3. Rest of South America

13.1. Key Insights

13.2. Market Size and Forecast, 2020-2033 (US$ Bn)
13.2.1. By Type
13.2.2. By Product
13.2.3. By Patient 
13.2.4. By Treatment Type
13.2.5. By Route of Administration 
13.2.6. By End User
13.2.7. By Distribution Channel
13.2.8. By Country 

14.1. Key Insights

14.2. Market Size and Forecast, 2020-2033 (US$ Bn)
14.2.1. By Type
14.2.2. By Product
14.2.3. By Patient 
14.2.4. By Treatment Type
14.2.5. By Route of Administration 
14.2.6. By End User
14.2.7. By Distribution Channel
14.2.8. By Country 

15.1. Key Insights

15.2. Market Size and Forecast, 2020-2033 (US$ Bn)
15.2.1. By Type
15.2.2. By Product
15.2.3. By Patient 
15.2.4. By Treatment Type
15.2.5. By Route of Administration 
15.2.6. By End User
15.2.7. By Distribution Channel
15.2.8. By Country 

16.1. Key Insights

16.2. Market Size and Forecast, 2020-2033 (US$ Bn)
16.2.1. By Type
16.2.2. By Product
16.2.3. By Patient 
16.2.4. By Treatment Type
16.2.5. By Route of Administration 
16.2.6. By End User
16.2.7. By Distribution Channel
16.2.8. By Country 

17.1. Key Insights

17.2. Market Size and Forecast, 2020-2033 (US$ Bn) 
17.2.1. By Type
17.2.2. By Product
17.2.3. By Patient 
17.2.4. By Treatment Type
17.2.5. By Route of Administration 
17.2.6. By End User
17.2.7. By Distribution Channel
17.2.8. By Country 

18.1. Industry Value Chain Analysis
18.1.1. Material Provider
18.1.2. Manufacturer
18.1.3. Distributor
18.1.4. End User
18.2. Industry Outlook

18.2.1. Hemophilia Prevalence Overview

18.3. PESTLE Analysis

18.4. Porter's Five Forces Analysis
18.4.1. Bargaining Power of Suppliers
18.4.2. Bargaining Power of Buyers
18.4.3. Threat of Substitutes
18.4.4. Threat of New Entrants
18.4.5. Degree of Competition

18.5. Market Dynamics and Trends
18.5.1. Growth Drivers
18.5.2. Challenges
18.5.3. Opportunity
18.5.4. Key Trends

18.6. Market Growth and Outlook
18.6.1. Market Revenue Estimates and Forecast (US$ Bn), 2020-2033

18.7. Competition Dashboard
18.7.1. Market Concentration Rate
18.7.2. Company Market Share Analysis (Value %), 2024
18.7.3. Competitor Mapping & Benchmarking

18.8. Japan Hemophilia Treatment Market Analysis
18.8.1. Key Insights
18.8.2. Market Size and Forecast, 2020-2033 (US$ Bn) 
18.8.2.1. By Type
18.8.2.2. By Product
18.8.2.3. By Patient 
18.8.2.4. By Treatment Type
18.8.2.5. By Route of Administration 
18.8.2.6. By End User
18.8.2.7. By Distribution Channel

19.1. Global
19.1.1. Bayer AG
19.1.2. Biogen Inc.
19.1.3. BioMarin Pharmaceutical Inc
19.1.4. Takeda Pharmaceuticals
19.1.5. CSL Behring LLC
19.1.6. F. Hoffmann-La Roche AG
19.1.7. Ferring B.V.
19.1.8. Genentech, Inc. (Roche Holding AG)
19.1.9. Grifols, S.A
19.1.10. Kedrion S.p.A
19.1.11. Medexus Pharmaceuticals Inc.
19.1.12. Novo Nordisk A/S
19.1.13. Octapharma AG
19.1.14. Pfizer Inc.
19.1.15. Sanofi SA
19.1.16. Swedish Orphan Biovitrum AB
19.1.17. Takeda Pharmaceuticals
19.1.18. Other Prominent Players

19.2. Japan
19.2.1. Chugai Pharmaceutical Co
19.2.2. Takeda Pharmaceutical Company Limited
19.2.3. KM Biologics
19.2.4. Other Prominent Players

20.1. List of Secondary Sources

20.2. Key Country Markets - Macro Economic Outlook/Indicator